Loading...
Market
What will be the revenue from sales of anticancer radiopharmaceuticals developed by Aktis Oncology and Eli Lilly by the end of 2025?
4
Resolution / Starting Odds
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Financial statements, press releases
Story
Aktis Oncology and Eli Lilly Announce $1.1 Billion Strategic Collaboration
May 21, 2024, 01:10 PM
Aktis Oncology announced on Tuesday a strategic collaboration with Eli Lilly to develop novel anticancer radiopharmaceuticals. The partnership includes milestone payments of up to $1.1 billion and royalties on sales. Aktis will receive an upfront payment of $60 million. This collaboration follows Eli Lilly's acquisition of radiopharma company Point Biopharma for $1.4 billion last year, highlighting Lilly's deepening investment in radiopharmaceuticals.
View original story
Similar markets
No similar markets found.